ATE220896T1 - Hydrogelformulierung mit gesteuerter freisetzung - Google Patents

Hydrogelformulierung mit gesteuerter freisetzung

Info

Publication number
ATE220896T1
ATE220896T1 AT95908570T AT95908570T ATE220896T1 AT E220896 T1 ATE220896 T1 AT E220896T1 AT 95908570 T AT95908570 T AT 95908570T AT 95908570 T AT95908570 T AT 95908570T AT E220896 T1 ATE220896 T1 AT E220896T1
Authority
AT
Austria
Prior art keywords
controlled release
hydrogel formulation
release hydrogel
hydrogel
drug
Prior art date
Application number
AT95908570T
Other languages
English (en)
Inventor
Chih-Ming Chen
Charles S L Chiao
Original Assignee
Andrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22721188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE220896(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Andrx Pharmaceuticals Inc filed Critical Andrx Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE220896T1 publication Critical patent/ATE220896T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
AT95908570T 1994-02-14 1995-01-18 Hydrogelformulierung mit gesteuerter freisetzung ATE220896T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/195,377 US5419917A (en) 1994-02-14 1994-02-14 Controlled release hydrogel formulation
PCT/US1995/000717 WO1995021607A1 (en) 1994-02-14 1995-01-18 Controlled release hydrogel formulation

Publications (1)

Publication Number Publication Date
ATE220896T1 true ATE220896T1 (de) 2002-08-15

Family

ID=22721188

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95908570T ATE220896T1 (de) 1994-02-14 1995-01-18 Hydrogelformulierung mit gesteuerter freisetzung

Country Status (10)

Country Link
US (1) US5419917A (de)
EP (1) EP0744942B1 (de)
JP (1) JPH10500658A (de)
AT (1) ATE220896T1 (de)
AU (1) AU680112B2 (de)
CA (1) CA2182587A1 (de)
DE (1) DE69527509T2 (de)
NZ (1) NZ279648A (de)
TW (1) TW340045B (de)
WO (1) WO1995021607A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
EP0814774B1 (de) * 1995-03-24 2005-10-19 Genzyme Corporation Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
WO1997026865A1 (en) * 1996-01-29 1997-07-31 Edward Mendell Co., Inc. Sustained release excipient
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
JP4221068B2 (ja) * 1997-12-17 2009-02-12 興和創薬株式会社 テオフィリン徐放性錠剤及びその製造方法
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
ES2221370T3 (es) 1998-04-03 2004-12-16 Egalet A/S Composicion de liberacion controlada.
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US6416786B1 (en) 1998-12-11 2002-07-09 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US20040234602A1 (en) * 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
JP5041651B2 (ja) * 2001-09-28 2012-10-03 ティーエヌティーギャンブル・インコーポレーテッド 生物体成分の送達系
EP1443910A1 (de) * 2001-11-02 2004-08-11 Wockhardt Limited Zubereitungen mit kontrollierter freigabe von makrolidantibiotika
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
PT1461017E (pt) * 2001-11-19 2006-07-31 Lupin Ltd Composicao farmaceutica para a libertacao controlada de um antibiotico beta-lactamico
CA2472188C (en) * 2002-01-18 2011-06-21 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
JP2006519753A (ja) 2002-11-15 2006-08-31 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
DE602004025159D1 (de) * 2003-03-26 2010-03-04 Egalet As Matrixzubereitungen für die kontrollierte Darreichung von Arzneistoffen
EP2301526B1 (de) 2003-03-26 2016-03-23 Egalet Ltd. System zur kontrollierten Freisetzung von Morphin
WO2006004774A2 (en) * 2004-06-28 2006-01-12 Stanford University Laulimalide analogues as therapeutic agents
EP1895989A2 (de) * 2005-06-03 2008-03-12 Egalet A/S Pharmazeutische feststoffzusammensetzung mit einem dispersionsmedium als erster fraktion und einer matrix als zweiter fraktion, wobei letztere wenigstens teilweise zunächst magen-darm-flüssigkeiten ausgesetzt wird
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
NZ577560A (en) * 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
CN101784263B (zh) * 2007-06-08 2012-11-07 贝林格尔.英格海姆国际有限公司 奈韦拉平的延长释放制剂
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
EP2155170A2 (de) * 2007-06-08 2010-02-24 Addrenex Pharmaceuticals, Inc. Formulierung mit verzögerter freisetzung und verfahren zur behandlung adrenerger unregelmässigkeiten
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
AU2009279372A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
WO2015073736A1 (en) 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Methods and compositions for treating adhd
BR112016020877B1 (pt) * 2014-03-11 2022-11-29 Redhill Biopharma Ltd Uso de ondansetron, uso de um núcleo compreendendo uma matriz polímera não iônica e comprimido
CN107920995A (zh) 2015-07-02 2018-04-17 路易斯威尔大学研究基金会 用于递送miRNA的源自可食用植物的微囊泡组合物和用于治疗癌症的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220152A (en) * 1978-05-08 1980-09-02 Pfizer Inc. Delivery system
US4220153A (en) * 1978-05-08 1980-09-02 Pfizer Inc. Controlled release delivery system
US4361545A (en) * 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4369172A (en) † 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) † 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4894233A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for decongestants
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4657757A (en) * 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
JPS62188031A (ja) † 1986-02-13 1987-08-17 Csk Corp 焦点整合位置検出方式
US5073380A (en) * 1987-07-27 1991-12-17 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
IE60311B1 (en) * 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
US5000962A (en) * 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
EP0484106A1 (de) * 1990-11-01 1992-05-06 Merck & Co. Inc. Geregelte Verabreichungszusammensetzungen
JPH04316515A (ja) * 1991-04-12 1992-11-06 Shin Etsu Chem Co Ltd 徐放性錠剤
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed

Also Published As

Publication number Publication date
AU1683695A (en) 1995-08-29
JPH10500658A (ja) 1998-01-20
WO1995021607A1 (en) 1995-08-17
CA2182587A1 (en) 1995-08-17
DE69527509D1 (de) 2002-08-29
DE69527509T2 (de) 2003-02-27
NZ279648A (en) 1997-06-24
TW340045B (en) 1998-09-11
EP0744942A4 (de) 1997-11-12
US5419917A (en) 1995-05-30
EP0744942A1 (de) 1996-12-04
EP0744942B1 (de) 2002-07-24
AU680112B2 (en) 1997-07-17

Similar Documents

Publication Publication Date Title
ATE220896T1 (de) Hydrogelformulierung mit gesteuerter freisetzung
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
BG102200A (en) Transcorneal system for the release of a medicament
AU3153097A (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
UA34466C2 (uk) Засіб для несистемної боротьби з паразитуючими комахами
NZ328898A (en) Sustained release formulation containing collagen and glycosaminoglycan additives
DK0810856T3 (da) Med bånd forsynet doseringsform af aktivt middel med forlænget frigivelse
BR0205721A (pt) Formulações de oximorfona de liberação controlada
ES2105218T3 (es) Composiciones estabilizadoras para dentaduras postizas.
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
ATE183392T1 (de) Transdermale therapeutische systeme zur verabreichung von serotoninagonisten
NO975140D0 (no) Transdermalt terapeutisk system (TTS) for administrasjon av testosteron
GB9907571D0 (en) Compounds
NO307364B1 (no) Anvendelse av melatoninderivater
ES2194129T3 (es) Compuestos farmaceuticos.
NZ515685A (en) Use of riluzole for the treatment of multiple sclerosis
UA32598C2 (uk) Спосіб одержання лікарської форми карбамазепіну
MY124089A (en) Use of cetirizine for preventing the onset of asthma
MX9606009A (es) Uso de 8,9-deshidroestrona como un antioxidante.
DK0669826T3 (da) (-)-Metrifonatholdigt lægemiddel
EP1082967A4 (de) Prophylaxe und behandlung von autoimmunen entmarkungskrankheiten
SE9501773D0 (sv) New use
JO2127B1 (en) How to prevent asthma